3
ABSTRACT
SKIN CANCER RISK IN MYCOSIS FUNGOIDES
PATIENTS TREATED WITH PUVA
Objective: Phototherapy is a common treatment modality in dermatology, which has several acute and chronic adverse affects. Among the phototherapy methods, PUVA treatment is considered to be associated with a relatively high risk for the development of secondary skin cancer compared to other phototherapy methods. However, there are no reports from our country related with the presence and extent of this risk. PUVA therapy administered in mycosis fungoides (MF) may take longer treatment duration than that in other diseases. Therefore, regular monitoring for the development of secondary skin cancer in MF patients treated with PUVA is important. The purpose of this study is to investigate the chronic effects of PUVA treatment on skin, especially for the development of skin cancer, in MF patients who were treated with PUVA and were followed for a long time.
Materials and Methods: This study was performed at the Department of Dermatology and Venereology, Istanbul Medicine Faculty, Istanbul University. MF patients who received PUVA therapy between the years of 1994 and 2006 and followed up for more than five years and who were still being followed up in 2012 in our outpatient clinic for MF were included in this study. A subset of patients was treated for several times with PUVA due to recurrence. The findings of the control dermatological examinations were retrospectively evaluated in terms of chronic skin side effects of PUVA treatment including cutaneous malignancy.
Findings: The study included 50 patients with MF (17 females, 33 males; mean age: 52.612.5 years). The average follow-up of these patients was 10.22.8 years, and the mean age of onset of PUVA therapy was 42.112.4 years. The average of total UVA dose was 552.8371.6 J/cm2. The average number of sessions was 163216.8 (median 110.5). Six patients (12%) had PUVA lentigines. Two patients (4%) developed skin cancer in the followup period (basal cell carcinoma and Bowen’s disease-in situ carcinoma-, in one patient each). Both patients had also PUVA lentigines. The mean treatment sessions in patients with skin cancer (295.57.8 sessions) was higher than those who did not develop skin cancer (157.5219.8 sessions). There was a significant relationship between the development of the PUVA lentigines and cutaneous malignancy (p=0.01).



12. SAYFAYA BENZER SAYFALAR

Kronik aktif hepatit b tanılı hastaların tedavi yanıtlarının değerlendirilmesi - Sayfa 7
SUMMARY Basarir Ibrahim, Assesement of treatment responses in patients with chronic active hepatitis B, Zonguldak Karaelmas University, Faculty of Medicine, Department of Internal Medicine Thesis, Zonguldak, 2011. In this study we aimed; patients with CHB who were treated in our hospital, retrospectively evaluatet by treatment response, biochemical, virologic, serologic and HBV DNA response. 241 ...
Puva ve dar bant uvb fototerapilerinin derideki etkilerinin dermoskopla izlenmesi - Sayfa 100
7. ABSTRACT Until now, dermoscopic side effects of PUVA and especially narrow band-UBV therapy which are continued to be used with increasing frequency in dermatology have only been examined on nevus. In present studies, however, changes on skin have been examined in clinical, histological and biochemical point of view. Dermoscopic changes of UV rays on skin are thus not sufficiently known. For ...

12. SAYFADAKI ANAHTAR KELIMELER

were
patient
patients
treatment
with
clinic


12. SAYFA ICERIGI

3
ABSTRACT
SKIN CANCER RISK IN MYCOSIS FUNGOIDES
PATIENTS TREATED WITH PUVA
Objective: Phototherapy is a common treatment modality in dermatology, which has several acute and chronic adverse affects. Among the phototherapy methods, PUVA treatment is considered to be associated with a relatively high risk for the development of secondary skin cancer compared to other phototherapy methods. However, there are no reports from our country related with the presence and extent of this risk. PUVA therapy administered in mycosis fungoides (MF) may take longer treatment duration than that in other diseases. Therefore, regular monitoring for the development of secondary skin cancer in MF patients treated with PUVA is important. The purpose of this study is to investigate the chronic effects of PUVA treatment on skin, especially for the development of skin cancer, in MF patients who were treated with PUVA and were followed for a long time.
Materials and Methods: This study was performed at the Department of Dermatology and Venereology, Istanbul Medicine Faculty, Istanbul University. MF patients who received PUVA therapy between the years of 1994 and 2006 and followed up for more than five years and who were still being followed up in 2012 in our outpatient clinic for MF were included in this study. A subset of patients was treated for several times with PUVA due to recurrence. The findings of the control dermatological examinations were retrospectively evaluated in terms of chronic skin side effects of PUVA treatment including cutaneous malignancy.
Findings: The study included 50 patients with MF (17 females, 33 males; mean age: 52.612.5 years). The average follow-up of these patients was 10.22.8 years, and the mean age of onset of PUVA therapy was 42.112.4 years. The average of total UVA dose was 552.8371.6 J/cm2. The average number of sessions was 163216.8 (median 110.5). Six patients (12%) had PUVA lentigines. Two patients (4%) developed skin cancer in the followup period (basal cell carcinoma and Bowen’s disease-in situ carcinoma-, in one patient each). Both patients had also PUVA lentigines. The mean treatment sessions in patients with skin cancer (295.57.8 sessions) was higher than those who did not develop skin cancer (157.5219.8 sessions). There was a significant relationship between the development of the PUVA lentigines and cutaneous malignancy (p=0.01).

İlgili Kaynaklar

single.php